European heart journal open · 2025
Development of three-step holistic care pathways to detect and manage comorbidities in patients with atrial fibrillation: the Horizon 2020 EHRA-PATHS consortium.
СтатьяКомментарийНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Önder Rana, Desteghe Lien, Vijgen Johan, Collins Rónán, Dabrowski Rafal, Farkowski Michal Miroslaw, de Oliveira Figueiredo Marcio Jansen, Hereijgers Maartje J M, Hofer Daniel, Lau Chu-Pak, Lee Geraldine, Linz Dominik, Lobeek Michelle, Lopez Teresa, McAuliffe Christine, Merino Jose Luis, Potpara Tatjana, Sanders Prashanthan, Shamloo Alireza Sepehri, Sterliński Maciej, Svennberg Emma, van Deutekom Colinda, Van Gelder Isabelle, Rienstra Michiel, Heidbuchel Hein
Аннотация
AIMS: Older patients with AF (≥65 years) have on average four additional comorbidities. Comorbidity management requires a systematic approach for identification, and interdisciplinary care, often lacking in clinical practice. The EHRA-PATHS project's overall aim is to create an approach to systematically address multimorbidity in older patients with AF.
METHODS AND RESULTS: This project involves a consortium of 14 partners from 11 European countries. The comorbidity care pathways were developed using a stepwise approach. (i) A literature study. (ii) Online meetings/discussions to create structured care pathways. (iii) A two-round Delphi study for consensus on the final pathways (agreement ≥80%) and to rank the comorbidities for priority. (iv) Selection of comorbidities for evaluation in the planned randomized controlled trial (RCT). Development of care pathways for 23 comorbidities or special clinical settings was obtained and agreed upon. The Delphi surveys were sent to 37 consortium experts. After round 1 (28 responses), 13 pathways reached an agreement ≥80%. Twelve adjusted pathways were presented in round 2 (27 responses), of which 8 received an agreement ≥80%. The last four pathways were finalized after expert consensus. Hypertension, heart failure, and overweight were ranked as the most important comorbidities.
CONCLUSION: A structured process of expert meetings and two Delphi rounds led to the development and ranking of 23 concise care pathways to identify and manage comorbidities in patients with AF. All pathways will be combined into a software tool, providing clinicians with a systematic approach to comorbidity management, which will be tested in the RCT of EHRA-PATHS.
METHODS AND RESULTS: This project involves a consortium of 14 partners from 11 European countries. The comorbidity care pathways were developed using a stepwise approach. (i) A literature study. (ii) Online meetings/discussions to create structured care pathways. (iii) A two-round Delphi study for consensus on the final pathways (agreement ≥80%) and to rank the comorbidities for priority. (iv) Selection of comorbidities for evaluation in the planned randomized controlled trial (RCT). Development of care pathways for 23 comorbidities or special clinical settings was obtained and agreed upon. The Delphi surveys were sent to 37 consortium experts. After round 1 (28 responses), 13 pathways reached an agreement ≥80%. Twelve adjusted pathways were presented in round 2 (27 responses), of which 8 received an agreement ≥80%. The last four pathways were finalized after expert consensus. Hypertension, heart failure, and overweight were ranked as the most important comorbidities.
CONCLUSION: A structured process of expert meetings and two Delphi rounds led to the development and ranking of 23 concise care pathways to identify and manage comorbidities in patients with AF. All pathways will be combined into a software tool, providing clinicians with a systematic approach to comorbidity management, which will be tested in the RCT of EHRA-PATHS.